VYNE is the name of the Dermatology therapeutics concern that formed when MNLO & FOMX combined. It markets 2 products: 1) Amzeeq has grown scips 20% since the beginning of the April shutdown. It is a treatment for cystic acne. 2) Zilxi, the rosacea treatment has improving health plan coverage. Potential future catalysts include potential ex-US partnerships and milestones for pipeline asset FCD105 ( a treatment for Acne Vulgaris). Earnings are 2/5/8/11. I'd be curious to hear the next earnings scheduled 11/4/20.